IRA will reduce out-of-pocket spending among some Part D enrollees by $7.4B in 2025, HHS report says

The In­fla­tion Re­duc­tion Act could low­er out-of-pock­et costs by around $7.4 bil­lion in 2025 for more than a third of all Amer­i­cans en­rolled in Medicare Part D, ac­cord­ing to a new re­port from the De­part­ment of Health and Hu­man Ser­vices’ Of­fice of Health Pol­i­cy.

The 41-page re­search pa­per, re­leased Thurs­day, mod­eled some of the IRA’s drug-re­lat­ed pro­vi­sions for 2024 and 2025. The pro­vi­sions, among oth­ers, in­clude the $2,000 a year out-of-pock­et spend­ing lim­it for Part D per year (in­dexed to in­fla­tion), a $35 per-month lim­it on cov­ered in­sulin prod­ucts, elim­i­nat­ing cost shar­ing on ACIP-rec­om­mend­ed adult vac­cines and ex­pan­sion of the low-in­come sub­sidy (LIS).

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN